Results of treatment of pituitary disease in multiple endocrine neoplasia, type I.
OBJECTIVE
The aim of the present study was to examine the clinical and pathological features of pituitary disease in patients with multiple endocrine neoplasia, Type I (MEN I) and to assess the prognosis.


METHODS
Fifty-two patients with pituitary disease and MEN I were studied retrospectively. Medical records were reviewed, and all of the patients known to be alive were sent a questionnaire to ascertain current disease status.


RESULTS
In 12 patients, pituitary disease was the initial manifestation of MEN I. The most common lesion was prolactinoma, followed, in frequency, by acromegaly and nonsecretory adenoma. Thirty-four of the patients had surgical treatment at the Mayo Clinic, Rochester, MN, as primary treatment, 3 had radiotherapy, and 12 received no specific therapy. Twelve patients had adjunctive radiotherapy postoperatively. Of the 34 patients receiving surgical treatment, 33 had adenoma and 1 had adenoma and pituitary hyperplasia. Immunocytochemical examination demonstrated that many tumors showed reactivity for more than one pituitary hormone. On survival analysis, no excess pituitary-related mortality was found, either in the surgically treated group or in the group as a whole.


CONCLUSIONS
On the basis of this study, we conclude that pituitary disease is frequently the initial manifestation of MEN I; that adenomas, particularly prolactinomas, are the rule and hyperplasia is rare; that a significant proportion of tumors are plurihormonal; and that excess pituitary-related mortality is not a factor in patients with MEN I.
O'Brien
T
T
Division of Endocrinology/Metabolism and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
O'Riordan
D S
DS
Gharib
H
H
Scheithauer
B W
BW
Ebersold
M J
MJ
van Heerden
J A
JA
D000172:Acromegaly / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D000236:Adenoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007016:Hypophysectomy; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D009384:Paraneoplastic Endocrine Syndromes / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D010902:Pituitary Gland / Q000473:pathology; D010910:Pituitary Irradiation; D010911:Pituitary Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D015175:Prolactinoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome